New hope for Hard-to-Treat prostate cancer? early trial launches
NCT ID NCT06785636
First seen Nov 17, 2025 · Last updated Jun 23, 2026 · Updated 36 times
Summary
This study tests a new oral drug called pocenbrodib, alone or with another drug (darolutamide), in 120 men with metastatic castration-resistant prostate cancer (mCRPC). The goal is to find safe doses and see if the combination can slow cancer growth. It is an early-stage trial, so results will guide future research rather than offer immediate treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer and Blood Research Center
RECRUITINGLos Alamitos, California, 90720, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Community Health Network
RECRUITINGIndianapolis, Indiana, 46250, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Duke University medical center
RECRUITINGDurham, North Carolina, 27710, United States
Contact
Contact Phone: •••-•••-••••
-
Emory University Hospital
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Johns Hopkins Hospital
RECRUITINGBaltimore, Maryland, 21287, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Karmanos Cancer Institute
RECRUITINGDetroit, Michigan, 48201, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
MemorialCare Orange Coast Medical Center
RECRUITINGFountain Valley, California, 92708, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Mount Sinai Medical Center
RECRUITINGMiami, Florida, 33140, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Oncology - Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact Phone: •••-•••-••••
Contact
-
Nebraska Cancer Specialists
RECRUITINGOmaha, Nebraska, 68130, United States
Contact Phone: •••-•••-••••
Contact
-
Ochsner
RECRUITINGJefferson, Louisiana, 70121, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Oncology Consultants, P.A
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-••••
Contact
-
Siteman Cancer Center
RECRUITINGSt Louis, Missouri, 63108, United States
Contact Phone: •••-•••-••••
Contact
-
Taylor Cancer Research Center
RECRUITINGMaumee, Ohio, 43537, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Ohio State University
RECRUITINGColumbus, Ohio, 43210, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Chicago
RECRUITINGChicago, Illinois, 60637, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Colorado Health
RECRUITINGAurora, Colorado, 80045, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Texas Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pocenbrodib (a targeted oral drug) alone or with darolutamide
What this could lead to
If successful, this could lead to a new treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong
This is an early-phase trial (Phase 1b/2a) focused on safety and dosing, so it is too soon to know if the drug will be effective. Side effects are unknown, and the combination may not work better than existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.